GRF:BME
Grifols SA Class A
€10.02
arrow_upward
+1.42%(+0.14) 1D
Oct 12, 5:36:02 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
€9.94
High
€10.08
Low
€9.94
Mkt. cap
6.06B
Avg. vol.
1.21M
Volume
1.21M
Dividend
2.32%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
15.07
52-wk high
€12.20
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
Open
€9.94
High
€10.08
Low
€9.94
Mkt. cap
6.06B
Avg. vol.
1.21M
Volume
1.21M
Dividend
2.32%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
15.07
52-wk high
€12.20
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
News stories
From web sources and news partners
ad-hoc-news.de
·
7 hours ago
Grifols stock trades at EUR 10.03 with EUR 6.8 billion market value
AD HOC NEWS
·
2 days ago
Grifols stock ends the week at EUR 9.88 within a EUR 9.73-9.97 range
AD HOC NEWS
·
3 days ago
Grifols stock after-hours at EUR 9.88: plus 0.51 percent
AD HOC NEWS
·
3 days ago
Grifols signed a 40 GWh PPA and Grifols stock gained 1.22 percent
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A